Topical 0.02% tacrolimus as adjunctive immunoprophylaxis in high-risk penetrating keratoplasty: a four-year retrospective study
International Ophthalmology · 19.06.2026 · 46 (1)
DOI: 10.1007/s10792-026-04140-5 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Ophthalmology, online erschienen am 19.06.2026. Verfasst von Luis Izquierdo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Investigación, Instituto de Ojos, OftalmoSalud, Av. Javier Prado Este 1142, San Isidro, Lima 27, Peru. izquierdojr2109@gmail.com. Hauptthemen laut MEDLINE: Keratoplasty, Penetrating, Tacrolimus, Graft Rejection, Corneal Diseases. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To describe the incidence and clinical profile of graft rejection in high-risk penetrating keratoplasty (PK) recipients treated with a compounded topical formulation of 0.02% tacrolimus combined with 1% prednisolone. METHODS: This retrospective observational study included 41 eyes from 41 high-risk PK patients operated between 2019 and 2023 at the Oftalmosalud Eye Institute (Lima, Peru), with a minimum follow-up of 12 months. All patients received adjunctive immunoprophylaxis with topical 0.02% tacrolimus and 1% prednisolone, initiated on the first postoperative day and maintained throughout follow-up. High-risk PK refers to corneal transplantation in eyes with predisposing factors for immune-mediated graft rejection. Graft rejection episodes were classified as reversible or irreversible based on clinical course and treatment response. RESULTS: Graft rejection occurred in 15 of 41 eyes (36.6%), with 60% of these episodes being reversible and 40% irreversible. The remaining 26 eyes (63.4%) maintained clear grafts without signs of rejection. The most frequent high-risk clinical features were corneal neovascularization in 21 eyes (51.2%), ocular surface disease in 9 eyes (21.9%), and persistent inflammation in 7 eyes (17.0%). No serious adverse events related to topical tacrolimus were observed. CONCLUSIONS: Topical 0.02% tacrolimus in combination with prednisolone may represent a safe adjunctive strategy in high-risk PK. These findings support the incorporation of topical tacrolimus into immunosuppressive regimens for high-risk corneal transplantation. Prospective controlled trials are warranted to confirm its long-term efficacy and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Investigación, Instituto de Ojos, OftalmoSalud, Av. Javier Prado Este 1142, San Isidro, Lima 27, Peru. izquierdojr2109@gmail.com.
- Departamento de Investigación, Instituto de Ojos, OftalmoSalud, Av. Javier Prado Este 1142, San Isidro, Lima 27, Peru.
Zitieren
APA
Izquierdo, L., Sánchez, N., Padró, J., Pomatanta, C., Rojas, R., Vera-Duarte, G. R., & Henriquez, M. A. (2026). Topical 0.02% tacrolimus as adjunctive immunoprophylaxis in high-risk penetrating keratoplasty: a four-year retrospective study. International Ophthalmology, 46(1). https://doi.org/10.1007/s10792-026-04140-5
Vancouver
Izquierdo L, Sánchez N, Padró J, Pomatanta C, Rojas R, Vera-Duarte GR, et al. Topical 0.02% tacrolimus as adjunctive immunoprophylaxis in high-risk penetrating keratoplasty: a four-year retrospective study. International Ophthalmology. 2026;46(1). doi:10.1007/s10792-026-04140-5
BibTeX
@article{Izquierdo2026,
author = {Izquierdo, Luis and Sánchez, Norka and Padró, Jorge and Pomatanta, Claudia and Rojas, Rolando and Vera-Duarte, Guillermo Raul and Henriquez, Maria A},
title = {Topical 0.02% tacrolimus as adjunctive immunoprophylaxis in high-risk penetrating keratoplasty: a four-year retrospective study},
journal = {International Ophthalmology},
year = {2026},
volume = {46},
number = {1},
doi = {10.1007/s10792-026-04140-5}
}
EUVIMED